Review Article
Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis
Table 2
Outcomes of the clinical trials included in the meta-analysis.
| | Study | Sample size | HCV-RNA(−) in serum | Mean log10 HCV-RNA reduction | SVR | Mean ALT level | Improved fibrosis scores | Total serious AEs | | Weeks 4 | Weeks 12 | Weeks 24 | Weeks 48 | Weeks 72 | Weeks 12 | Weeks 24 | Weeks 48 | Weeks 48 |
| Berenguer,
2008 [12] | TG: 86 | NR | NR | NR | NR | NR | NR | NR | NR | 33/89 (37%) | NR | NR | NR | | CG: 75 | NR | NR | NR | NR | NR | NR | NR | NR | 0 | NR | NR | NR |
| Castells et al.,
2005 [13] | TG: 24 | NR | NR | NR | 14/24 (58%) | NR | 1.07 | 1.46 | 1.9 | 8/23 (34.7%) | 45 ± 45 | NR | NR | | CG: 24 | NR | NR | NR | 0/24 (0%) | NR | 0 | 0 | 0 | 0/24 (0%) | 74 ± 63 | NR | NR |
| Chalasani et al.,
2005 [14] | TG: 33 | 4/33 (12%) | 10/33 (30%) | 10/33 (30%) | 9/33 (27%) | 4/33 (12%) | NR | NR | NR | 4/33 (12%) | NR | 3/33 (10%) | 5/33 (13%) | | CG: 32 | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) | NR | NR | NR | 0/32 (0%) | NR | 2/32 (8%) | 3/32 (11%) |
| Samuel et al.,
2003 [11] | TG: 28 | 3/28 (10.7%) | 5/28 (17.9%) | 8/28 (28.6%) | 9/28 (32%) | 6/28 (21.4%) | NR | (2.88 ± 1.86) | (2.82 ± 2.16) | 5/23 (21%) | 32 ± 22 | 4/28 (14%) | 21 (88%) | | CG: 24 | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) | NR | 0 | 0 | 0 | 64 ± 40.8 | 1/24 (4%) | 3 (13%) |
|
|
TG: treatment group; CG: control group; NR: not reported; ALT: alanine aminotransferase; AE: adverse event.
|
